nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—prostate cancer—urinary bladder cancer	0.244	1	CtDrD
Mitoxantrone—Topoisomerase Inhibitors—Etoposide—urinary bladder cancer	0.199	0.43	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Epirubicin—urinary bladder cancer	0.137	0.296	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Doxorubicin—urinary bladder cancer	0.127	0.274	CiPCiCtD
Mitoxantrone—TOP2A—Valrubicin—urinary bladder cancer	0.0947	0.468	CbGbCtD
Mitoxantrone—TOP2A—Epirubicin—urinary bladder cancer	0.0143	0.0709	CbGbCtD
Mitoxantrone—TOP2A—Etoposide—urinary bladder cancer	0.0112	0.0553	CbGbCtD
Mitoxantrone—ABCC1—Epirubicin—urinary bladder cancer	0.00795	0.0393	CbGbCtD
Mitoxantrone—TOP2A—Doxorubicin—urinary bladder cancer	0.00763	0.0377	CbGbCtD
Mitoxantrone—ABCB1—Mitomycin—urinary bladder cancer	0.00728	0.036	CbGbCtD
Mitoxantrone—ABCC1—Etoposide—urinary bladder cancer	0.0062	0.0306	CbGbCtD
Mitoxantrone—CYP1B1—Doxorubicin—urinary bladder cancer	0.00595	0.0294	CbGbCtD
Mitoxantrone—ABCG2—Fluorouracil—urinary bladder cancer	0.00497	0.0246	CbGbCtD
Mitoxantrone—ABCG2—Carboplatin—urinary bladder cancer	0.00494	0.0244	CbGbCtD
Mitoxantrone—ABCC1—Doxorubicin—urinary bladder cancer	0.00423	0.0209	CbGbCtD
Mitoxantrone—ABCG2—Cisplatin—urinary bladder cancer	0.00422	0.0209	CbGbCtD
Mitoxantrone—ABCG2—Etoposide—urinary bladder cancer	0.00415	0.0205	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—urinary bladder cancer	0.00409	0.0202	CbGbCtD
Mitoxantrone—CYP3A4—Thiotepa—urinary bladder cancer	0.0033	0.0163	CbGbCtD
Mitoxantrone—CYP2E1—Etoposide—urinary bladder cancer	0.00296	0.0146	CbGbCtD
Mitoxantrone—ABCG2—Doxorubicin—urinary bladder cancer	0.00283	0.014	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—urinary bladder cancer	0.00274	0.0135	CbGbCtD
Mitoxantrone—ABCB1—Gemcitabine—urinary bladder cancer	0.00209	0.0104	CbGbCtD
Mitoxantrone—ABCB1—Cisplatin—urinary bladder cancer	0.00152	0.00752	CbGbCtD
Mitoxantrone—ABCB1—Etoposide—urinary bladder cancer	0.0015	0.00739	CbGbCtD
Mitoxantrone—ABCB1—Doxorubicin—urinary bladder cancer	0.00102	0.00504	CbGbCtD
Mitoxantrone—BTK—prostate gland—urinary bladder cancer	0.00101	0.062	CbGeAlD
Mitoxantrone—ABCB1—Methotrexate—urinary bladder cancer	0.000988	0.00488	CbGbCtD
Mitoxantrone—SLC47A2—renal system—urinary bladder cancer	0.000915	0.0561	CbGeAlD
Mitoxantrone—CYP3A4—Etoposide—urinary bladder cancer	0.000896	0.00443	CbGbCtD
Mitoxantrone—PIM1—prostate gland—urinary bladder cancer	0.000877	0.0537	CbGeAlD
Mitoxantrone—PIM1—seminal vesicle—urinary bladder cancer	0.000742	0.0454	CbGeAlD
Mitoxantrone—SLC47A2—vagina—urinary bladder cancer	0.000663	0.0406	CbGeAlD
Mitoxantrone—CYP2E1—urine—urinary bladder cancer	0.000619	0.0379	CbGeAlD
Mitoxantrone—CYP3A4—Doxorubicin—urinary bladder cancer	0.000611	0.00302	CbGbCtD
Mitoxantrone—PIM1—renal system—urinary bladder cancer	0.000598	0.0366	CbGeAlD
Mitoxantrone—PIM1—urethra—urinary bladder cancer	0.000587	0.036	CbGeAlD
Mitoxantrone—TOP2A—prostate gland—urinary bladder cancer	0.000515	0.0315	CbGeAlD
Mitoxantrone—BTK—vagina—urinary bladder cancer	0.0005	0.0306	CbGeAlD
Mitoxantrone—CYP3A4—urine—urinary bladder cancer	0.000498	0.0305	CbGeAlD
Mitoxantrone—PIM1—female reproductive system—urinary bladder cancer	0.000479	0.0293	CbGeAlD
Mitoxantrone—SLC47A1—prostate gland—urinary bladder cancer	0.00047	0.0288	CbGeAlD
Mitoxantrone—PIM1—vagina—urinary bladder cancer	0.000433	0.0265	CbGeAlD
Mitoxantrone—SLC47A1—seminal vesicle—urinary bladder cancer	0.000398	0.0243	CbGeAlD
Mitoxantrone—CYP1B1—prostate gland—urinary bladder cancer	0.000344	0.0211	CbGeAlD
Mitoxantrone—BTK—lymph node—urinary bladder cancer	0.000323	0.0198	CbGeAlD
Mitoxantrone—SLC47A1—renal system—urinary bladder cancer	0.00032	0.0196	CbGeAlD
Mitoxantrone—SLC47A1—urethra—urinary bladder cancer	0.000315	0.0193	CbGeAlD
Mitoxantrone—ABCC1—prostate gland—urinary bladder cancer	0.00031	0.019	CbGeAlD
Mitoxantrone—PIM1—lymph node—urinary bladder cancer	0.00028	0.0172	CbGeAlD
Mitoxantrone—ABCC1—seminal vesicle—urinary bladder cancer	0.000262	0.0161	CbGeAlD
Mitoxantrone—SLC47A1—female reproductive system—urinary bladder cancer	0.000257	0.0157	CbGeAlD
Mitoxantrone—ABCG2—prostate gland—urinary bladder cancer	0.000257	0.0157	CbGeAlD
Mitoxantrone—TOP2A—vagina—urinary bladder cancer	0.000254	0.0156	CbGeAlD
Mitoxantrone—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000244	0.0149	CbGeAlD
Mitoxantrone—CYP1B1—renal system—urinary bladder cancer	0.000235	0.0144	CbGeAlD
Mitoxantrone—SLC47A1—vagina—urinary bladder cancer	0.000232	0.0142	CbGeAlD
Mitoxantrone—CYP2E1—prostate gland—urinary bladder cancer	0.000222	0.0136	CbGeAlD
Mitoxantrone—ABCG2—seminal vesicle—urinary bladder cancer	0.000217	0.0133	CbGeAlD
Mitoxantrone—ABCC1—urethra—urinary bladder cancer	0.000207	0.0127	CbGeAlD
Mitoxantrone—CYP1B1—female reproductive system—urinary bladder cancer	0.000188	0.0115	CbGeAlD
Mitoxantrone—CYP2E1—seminal vesicle—urinary bladder cancer	0.000188	0.0115	CbGeAlD
Mitoxantrone—ABCG2—urethra—urinary bladder cancer	0.000172	0.0105	CbGeAlD
Mitoxantrone—TOP2A—lymph node—urinary bladder cancer	0.000164	0.0101	CbGeAlD
Mitoxantrone—ABCC1—vagina—urinary bladder cancer	0.000153	0.00937	CbGeAlD
Mitoxantrone—CYP2E1—renal system—urinary bladder cancer	0.000151	0.00927	CbGeAlD
Mitoxantrone—SLC47A1—lymph node—urinary bladder cancer	0.00015	0.00919	CbGeAlD
Mitoxantrone—CYP2E1—urethra—urinary bladder cancer	0.000149	0.00911	CbGeAlD
Mitoxantrone—ABCG2—vagina—urinary bladder cancer	0.000127	0.00776	CbGeAlD
Mitoxantrone—ABCB1—prostate gland—urinary bladder cancer	0.000126	0.00775	CbGeAlD
Mitoxantrone—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000126	0.125	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000126	0.125	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000126	0.125	CbGdCrCtD
Mitoxantrone—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000126	0.125	CbGdCrCtD
Mitoxantrone—CYP3A4—renal system—urinary bladder cancer	0.000122	0.00746	CbGeAlD
Mitoxantrone—CYP2E1—female reproductive system—urinary bladder cancer	0.000121	0.00742	CbGeAlD
Mitoxantrone—CYP1B1—lymph node—urinary bladder cancer	0.00011	0.00674	CbGeAlD
Mitoxantrone—ABCB1—seminal vesicle—urinary bladder cancer	0.000107	0.00655	CbGeAlD
Mitoxantrone—ABCC1—lymph node—urinary bladder cancer	9.89e-05	0.00606	CbGeAlD
Mitoxantrone—CYP3A4—female reproductive system—urinary bladder cancer	9.75e-05	0.00597	CbGeAlD
Mitoxantrone—ABCB1—epithelium—urinary bladder cancer	9.29e-05	0.00569	CbGeAlD
Mitoxantrone—ABCB1—renal system—urinary bladder cancer	8.62e-05	0.00528	CbGeAlD
Mitoxantrone—ABCB1—urethra—urinary bladder cancer	8.47e-05	0.00519	CbGeAlD
Mitoxantrone—TOP2A—Teniposide—Etoposide—urinary bladder cancer	8.44e-05	0.0835	CbGdCrCtD
Mitoxantrone—TOP2A—Podofilox—Etoposide—urinary bladder cancer	8.44e-05	0.0835	CbGdCrCtD
Mitoxantrone—ABCG2—lymph node—urinary bladder cancer	8.19e-05	0.00502	CbGeAlD
Mitoxantrone—ABCB1—female reproductive system—urinary bladder cancer	6.9e-05	0.00423	CbGeAlD
Mitoxantrone—ABCB1—vagina—urinary bladder cancer	6.24e-05	0.00382	CbGeAlD
Mitoxantrone—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	4.75e-05	0.047	CbGdCrCtD
Mitoxantrone—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	4.4e-05	0.0436	CbGdCrCtD
Mitoxantrone—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	4.4e-05	0.0436	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	4.4e-05	0.0436	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	4.07e-05	0.0403	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	4.07e-05	0.0403	CbGdCrCtD
Mitoxantrone—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	4.07e-05	0.0403	CbGdCrCtD
Mitoxantrone—ABCB1—lymph node—urinary bladder cancer	4.04e-05	0.00247	CbGeAlD
Mitoxantrone—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	3.4e-05	0.0337	CbGdCrCtD
Mitoxantrone—Urticaria—Fluorouracil—urinary bladder cancer	2.74e-05	0.000563	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—urinary bladder cancer	2.74e-05	0.000562	CcSEcCtD
Mitoxantrone—Body temperature increased—Fluorouracil—urinary bladder cancer	2.73e-05	0.000561	CcSEcCtD
Mitoxantrone—Sweating—Methotrexate—urinary bladder cancer	2.7e-05	0.000555	CcSEcCtD
Mitoxantrone—Feeling abnormal—Cisplatin—urinary bladder cancer	2.7e-05	0.000554	CcSEcCtD
Mitoxantrone—Paraesthesia—Etoposide—urinary bladder cancer	2.69e-05	0.000553	CcSEcCtD
Mitoxantrone—Weight increased—Epirubicin—urinary bladder cancer	2.69e-05	0.000553	CcSEcCtD
Mitoxantrone—Haematuria—Methotrexate—urinary bladder cancer	2.69e-05	0.000552	CcSEcCtD
Mitoxantrone—Weight decreased—Epirubicin—urinary bladder cancer	2.67e-05	0.000549	CcSEcCtD
Mitoxantrone—Dyspnoea—Etoposide—urinary bladder cancer	2.67e-05	0.000549	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Epirubicin—urinary bladder cancer	2.67e-05	0.000548	CcSEcCtD
Mitoxantrone—Somnolence—Etoposide—urinary bladder cancer	2.67e-05	0.000548	CcSEcCtD
Mitoxantrone—Vomiting—Thiotepa—urinary bladder cancer	2.65e-05	0.000545	CcSEcCtD
Mitoxantrone—Pneumonia—Epirubicin—urinary bladder cancer	2.65e-05	0.000544	CcSEcCtD
Mitoxantrone—Drowsiness—Epirubicin—urinary bladder cancer	2.64e-05	0.000541	CcSEcCtD
Mitoxantrone—Rash—Thiotepa—urinary bladder cancer	2.63e-05	0.000541	CcSEcCtD
Mitoxantrone—Dermatitis—Thiotepa—urinary bladder cancer	2.63e-05	0.00054	CcSEcCtD
Mitoxantrone—Agranulocytosis—Methotrexate—urinary bladder cancer	2.63e-05	0.00054	CcSEcCtD
Mitoxantrone—Headache—Thiotepa—urinary bladder cancer	2.62e-05	0.000537	CcSEcCtD
Mitoxantrone—Decreased appetite—Etoposide—urinary bladder cancer	2.61e-05	0.000535	CcSEcCtD
Mitoxantrone—Pancytopenia—Doxorubicin—urinary bladder cancer	2.6e-05	0.000533	CcSEcCtD
Mitoxantrone—Renal failure—Epirubicin—urinary bladder cancer	2.59e-05	0.000532	CcSEcCtD
Mitoxantrone—Body temperature increased—Cisplatin—urinary bladder cancer	2.59e-05	0.000531	CcSEcCtD
Mitoxantrone—Fatigue—Etoposide—urinary bladder cancer	2.59e-05	0.000531	CcSEcCtD
Mitoxantrone—Stomatitis—Epirubicin—urinary bladder cancer	2.57e-05	0.000528	CcSEcCtD
Mitoxantrone—Jaundice—Epirubicin—urinary bladder cancer	2.57e-05	0.000528	CcSEcCtD
Mitoxantrone—Constipation—Etoposide—urinary bladder cancer	2.56e-05	0.000527	CcSEcCtD
Mitoxantrone—Pain—Etoposide—urinary bladder cancer	2.56e-05	0.000527	CcSEcCtD
Mitoxantrone—Urinary tract infection—Epirubicin—urinary bladder cancer	2.56e-05	0.000526	CcSEcCtD
Mitoxantrone—Conjunctivitis—Epirubicin—urinary bladder cancer	2.56e-05	0.000526	CcSEcCtD
Mitoxantrone—Neutropenia—Doxorubicin—urinary bladder cancer	2.56e-05	0.000525	CcSEcCtD
Mitoxantrone—Hypersensitivity—Fluorouracil—urinary bladder cancer	2.54e-05	0.000522	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	2.54e-05	0.000522	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—urinary bladder cancer	2.54e-05	0.000522	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—urinary bladder cancer	2.53e-05	0.000519	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—urinary bladder cancer	2.53e-05	0.000519	CcSEcCtD
Mitoxantrone—Sweating—Epirubicin—urinary bladder cancer	2.53e-05	0.000519	CcSEcCtD
Mitoxantrone—Asthenia—Gemcitabine—urinary bladder cancer	2.52e-05	0.000517	CcSEcCtD
Mitoxantrone—Haematuria—Epirubicin—urinary bladder cancer	2.51e-05	0.000516	CcSEcCtD
Mitoxantrone—Pharyngitis—Methotrexate—urinary bladder cancer	2.51e-05	0.000515	CcSEcCtD
Mitoxantrone—Weight increased—Doxorubicin—urinary bladder cancer	2.49e-05	0.000511	CcSEcCtD
Mitoxantrone—Nausea—Thiotepa—urinary bladder cancer	2.48e-05	0.000509	CcSEcCtD
Mitoxantrone—Weight decreased—Doxorubicin—urinary bladder cancer	2.47e-05	0.000508	CcSEcCtD
Mitoxantrone—Sinusitis—Epirubicin—urinary bladder cancer	2.47e-05	0.000508	CcSEcCtD
Mitoxantrone—Feeling abnormal—Etoposide—urinary bladder cancer	2.47e-05	0.000508	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	2.47e-05	0.000507	CcSEcCtD
Mitoxantrone—Agranulocytosis—Epirubicin—urinary bladder cancer	2.46e-05	0.000505	CcSEcCtD
Mitoxantrone—Pneumonia—Doxorubicin—urinary bladder cancer	2.45e-05	0.000504	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Etoposide—urinary bladder cancer	2.45e-05	0.000504	CcSEcCtD
Mitoxantrone—Drowsiness—Doxorubicin—urinary bladder cancer	2.44e-05	0.000501	CcSEcCtD
Mitoxantrone—Hypersensitivity—Cisplatin—urinary bladder cancer	2.41e-05	0.000495	CcSEcCtD
Mitoxantrone—Bradycardia—Epirubicin—urinary bladder cancer	2.41e-05	0.000495	CcSEcCtD
Mitoxantrone—Diarrhoea—Gemcitabine—urinary bladder cancer	2.4e-05	0.000494	CcSEcCtD
Mitoxantrone—Renal failure—Doxorubicin—urinary bladder cancer	2.4e-05	0.000492	CcSEcCtD
Mitoxantrone—Urticaria—Etoposide—urinary bladder cancer	2.38e-05	0.000489	CcSEcCtD
Mitoxantrone—Haemoglobin—Epirubicin—urinary bladder cancer	2.38e-05	0.000488	CcSEcCtD
Mitoxantrone—Jaundice—Doxorubicin—urinary bladder cancer	2.38e-05	0.000488	CcSEcCtD
Mitoxantrone—Stomatitis—Doxorubicin—urinary bladder cancer	2.38e-05	0.000488	CcSEcCtD
Mitoxantrone—Rhinitis—Epirubicin—urinary bladder cancer	2.37e-05	0.000487	CcSEcCtD
Mitoxantrone—Abdominal pain—Etoposide—urinary bladder cancer	2.37e-05	0.000487	CcSEcCtD
Mitoxantrone—Body temperature increased—Etoposide—urinary bladder cancer	2.37e-05	0.000487	CcSEcCtD
Mitoxantrone—Conjunctivitis—Doxorubicin—urinary bladder cancer	2.37e-05	0.000487	CcSEcCtD
Mitoxantrone—Urinary tract infection—Doxorubicin—urinary bladder cancer	2.37e-05	0.000487	CcSEcCtD
Mitoxantrone—Haemorrhage—Epirubicin—urinary bladder cancer	2.37e-05	0.000486	CcSEcCtD
Mitoxantrone—Hepatitis—Epirubicin—urinary bladder cancer	2.37e-05	0.000486	CcSEcCtD
Mitoxantrone—Diarrhoea—Fluorouracil—urinary bladder cancer	2.36e-05	0.000485	CcSEcCtD
Mitoxantrone—Asthenia—Cisplatin—urinary bladder cancer	2.35e-05	0.000482	CcSEcCtD
Mitoxantrone—Pharyngitis—Epirubicin—urinary bladder cancer	2.35e-05	0.000482	CcSEcCtD
Mitoxantrone—Sweating—Doxorubicin—urinary bladder cancer	2.34e-05	0.00048	CcSEcCtD
Mitoxantrone—Haematuria—Doxorubicin—urinary bladder cancer	2.33e-05	0.000478	CcSEcCtD
Mitoxantrone—Sinusitis—Doxorubicin—urinary bladder cancer	2.29e-05	0.00047	CcSEcCtD
Mitoxantrone—Agranulocytosis—Doxorubicin—urinary bladder cancer	2.28e-05	0.000467	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—urinary bladder cancer	2.27e-05	0.000466	CcSEcCtD
Mitoxantrone—Diarrhoea—Cisplatin—urinary bladder cancer	2.24e-05	0.00046	CcSEcCtD
Mitoxantrone—Alopecia—Methotrexate—urinary bladder cancer	2.23e-05	0.000459	CcSEcCtD
Mitoxantrone—Vomiting—Gemcitabine—urinary bladder cancer	2.23e-05	0.000459	CcSEcCtD
Mitoxantrone—Bradycardia—Doxorubicin—urinary bladder cancer	2.23e-05	0.000458	CcSEcCtD
Mitoxantrone—Rash—Gemcitabine—urinary bladder cancer	2.21e-05	0.000455	CcSEcCtD
Mitoxantrone—Dermatitis—Gemcitabine—urinary bladder cancer	2.21e-05	0.000454	CcSEcCtD
Mitoxantrone—Hypersensitivity—Etoposide—urinary bladder cancer	2.21e-05	0.000454	CcSEcCtD
Mitoxantrone—Erythema—Methotrexate—urinary bladder cancer	2.2e-05	0.000452	CcSEcCtD
Mitoxantrone—Haemoglobin—Doxorubicin—urinary bladder cancer	2.2e-05	0.000452	CcSEcCtD
Mitoxantrone—Headache—Gemcitabine—urinary bladder cancer	2.2e-05	0.000452	CcSEcCtD
Mitoxantrone—Vomiting—Fluorouracil—urinary bladder cancer	2.2e-05	0.000451	CcSEcCtD
Mitoxantrone—Rhinitis—Doxorubicin—urinary bladder cancer	2.19e-05	0.000451	CcSEcCtD
Mitoxantrone—Haemorrhage—Doxorubicin—urinary bladder cancer	2.19e-05	0.00045	CcSEcCtD
Mitoxantrone—Hepatitis—Doxorubicin—urinary bladder cancer	2.19e-05	0.00045	CcSEcCtD
Mitoxantrone—Rash—Fluorouracil—urinary bladder cancer	2.18e-05	0.000447	CcSEcCtD
Mitoxantrone—Dermatitis—Fluorouracil—urinary bladder cancer	2.18e-05	0.000447	CcSEcCtD
Mitoxantrone—Pharyngitis—Doxorubicin—urinary bladder cancer	2.17e-05	0.000446	CcSEcCtD
Mitoxantrone—Headache—Fluorouracil—urinary bladder cancer	2.16e-05	0.000444	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—urinary bladder cancer	2.16e-05	0.000443	CcSEcCtD
Mitoxantrone—Asthenia—Etoposide—urinary bladder cancer	2.15e-05	0.000442	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—urinary bladder cancer	2.13e-05	0.000437	CcSEcCtD
Mitoxantrone—Chills—Epirubicin—urinary bladder cancer	2.12e-05	0.000436	CcSEcCtD
Mitoxantrone—Arrhythmia—Epirubicin—urinary bladder cancer	2.11e-05	0.000434	CcSEcCtD
Mitoxantrone—Alopecia—Epirubicin—urinary bladder cancer	2.09e-05	0.000429	CcSEcCtD
Mitoxantrone—Nausea—Gemcitabine—urinary bladder cancer	2.09e-05	0.000428	CcSEcCtD
Mitoxantrone—Vomiting—Cisplatin—urinary bladder cancer	2.08e-05	0.000427	CcSEcCtD
Mitoxantrone—Vision blurred—Methotrexate—urinary bladder cancer	2.07e-05	0.000426	CcSEcCtD
Mitoxantrone—Rash—Cisplatin—urinary bladder cancer	2.06e-05	0.000424	CcSEcCtD
Mitoxantrone—Dermatitis—Cisplatin—urinary bladder cancer	2.06e-05	0.000423	CcSEcCtD
Mitoxantrone—Erythema—Epirubicin—urinary bladder cancer	2.06e-05	0.000423	CcSEcCtD
Mitoxantrone—Diarrhoea—Etoposide—urinary bladder cancer	2.05e-05	0.000421	CcSEcCtD
Mitoxantrone—Nausea—Fluorouracil—urinary bladder cancer	2.05e-05	0.000421	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Methotrexate—urinary bladder cancer	2.04e-05	0.000419	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—urinary bladder cancer	2.03e-05	0.000418	CcSEcCtD
Mitoxantrone—Dysgeusia—Epirubicin—urinary bladder cancer	2.02e-05	0.000414	CcSEcCtD
Mitoxantrone—Back pain—Epirubicin—urinary bladder cancer	1.99e-05	0.000409	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—urinary bladder cancer	1.98e-05	0.000408	CcSEcCtD
Mitoxantrone—Leukopenia—Methotrexate—urinary bladder cancer	1.97e-05	0.000405	CcSEcCtD
Mitoxantrone—Chills—Doxorubicin—urinary bladder cancer	1.96e-05	0.000403	CcSEcCtD
Mitoxantrone—Arrhythmia—Doxorubicin—urinary bladder cancer	1.96e-05	0.000402	CcSEcCtD
Mitoxantrone—Nausea—Cisplatin—urinary bladder cancer	1.94e-05	0.000399	CcSEcCtD
Mitoxantrone—Vision blurred—Epirubicin—urinary bladder cancer	1.94e-05	0.000399	CcSEcCtD
Mitoxantrone—Alopecia—Doxorubicin—urinary bladder cancer	1.93e-05	0.000397	CcSEcCtD
Mitoxantrone—Cough—Methotrexate—urinary bladder cancer	1.92e-05	0.000394	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Epirubicin—urinary bladder cancer	1.91e-05	0.000392	CcSEcCtD
Mitoxantrone—Convulsion—Methotrexate—urinary bladder cancer	1.91e-05	0.000392	CcSEcCtD
Mitoxantrone—Vomiting—Etoposide—urinary bladder cancer	1.91e-05	0.000392	CcSEcCtD
Mitoxantrone—Erythema—Doxorubicin—urinary bladder cancer	1.91e-05	0.000391	CcSEcCtD
Mitoxantrone—Anaemia—Epirubicin—urinary bladder cancer	1.9e-05	0.000391	CcSEcCtD
Mitoxantrone—Rash—Etoposide—urinary bladder cancer	1.89e-05	0.000388	CcSEcCtD
Mitoxantrone—Dermatitis—Etoposide—urinary bladder cancer	1.89e-05	0.000388	CcSEcCtD
Mitoxantrone—Headache—Etoposide—urinary bladder cancer	1.88e-05	0.000386	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—urinary bladder cancer	1.87e-05	0.000385	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—urinary bladder cancer	1.87e-05	0.000385	CcSEcCtD
Mitoxantrone—Arthralgia—Methotrexate—urinary bladder cancer	1.87e-05	0.000385	CcSEcCtD
Mitoxantrone—Dysgeusia—Doxorubicin—urinary bladder cancer	1.87e-05	0.000383	CcSEcCtD
Mitoxantrone—Malaise—Epirubicin—urinary bladder cancer	1.86e-05	0.000381	CcSEcCtD
Mitoxantrone—Discomfort—Methotrexate—urinary bladder cancer	1.85e-05	0.00038	CcSEcCtD
Mitoxantrone—Leukopenia—Epirubicin—urinary bladder cancer	1.84e-05	0.000379	CcSEcCtD
Mitoxantrone—Back pain—Doxorubicin—urinary bladder cancer	1.84e-05	0.000379	CcSEcCtD
Mitoxantrone—Confusional state—Methotrexate—urinary bladder cancer	1.81e-05	0.000372	CcSEcCtD
Mitoxantrone—Cough—Epirubicin—urinary bladder cancer	1.8e-05	0.000369	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Methotrexate—urinary bladder cancer	1.8e-05	0.000369	CcSEcCtD
Mitoxantrone—Vision blurred—Doxorubicin—urinary bladder cancer	1.8e-05	0.000369	CcSEcCtD
Mitoxantrone—Convulsion—Epirubicin—urinary bladder cancer	1.78e-05	0.000367	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—urinary bladder cancer	1.78e-05	0.000367	CcSEcCtD
Mitoxantrone—Nausea—Etoposide—urinary bladder cancer	1.78e-05	0.000366	CcSEcCtD
Mitoxantrone—Hypertension—Epirubicin—urinary bladder cancer	1.78e-05	0.000365	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	1.77e-05	0.000363	CcSEcCtD
Mitoxantrone—Anaemia—Doxorubicin—urinary bladder cancer	1.76e-05	0.000362	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.76e-05	0.000361	CcSEcCtD
Mitoxantrone—Myalgia—Epirubicin—urinary bladder cancer	1.75e-05	0.00036	CcSEcCtD
Mitoxantrone—Chest pain—Epirubicin—urinary bladder cancer	1.75e-05	0.00036	CcSEcCtD
Mitoxantrone—Arthralgia—Epirubicin—urinary bladder cancer	1.75e-05	0.00036	CcSEcCtD
Mitoxantrone—Anxiety—Epirubicin—urinary bladder cancer	1.75e-05	0.000359	CcSEcCtD
Mitoxantrone—Skin disorder—Methotrexate—urinary bladder cancer	1.74e-05	0.000358	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Methotrexate—urinary bladder cancer	1.74e-05	0.000357	CcSEcCtD
Mitoxantrone—Discomfort—Epirubicin—urinary bladder cancer	1.73e-05	0.000356	CcSEcCtD
Mitoxantrone—Malaise—Doxorubicin—urinary bladder cancer	1.72e-05	0.000353	CcSEcCtD
Mitoxantrone—Anorexia—Methotrexate—urinary bladder cancer	1.71e-05	0.000352	CcSEcCtD
Mitoxantrone—Leukopenia—Doxorubicin—urinary bladder cancer	1.71e-05	0.00035	CcSEcCtD
Mitoxantrone—Confusional state—Epirubicin—urinary bladder cancer	1.7e-05	0.000348	CcSEcCtD
Mitoxantrone—Oedema—Epirubicin—urinary bladder cancer	1.68e-05	0.000345	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Epirubicin—urinary bladder cancer	1.68e-05	0.000345	CcSEcCtD
Mitoxantrone—Hypotension—Methotrexate—urinary bladder cancer	1.68e-05	0.000345	CcSEcCtD
Mitoxantrone—Infection—Epirubicin—urinary bladder cancer	1.67e-05	0.000343	CcSEcCtD
Mitoxantrone—Cough—Doxorubicin—urinary bladder cancer	1.66e-05	0.000342	CcSEcCtD
Mitoxantrone—Shock—Epirubicin—urinary bladder cancer	1.65e-05	0.00034	CcSEcCtD
Mitoxantrone—Convulsion—Doxorubicin—urinary bladder cancer	1.65e-05	0.000339	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.65e-05	0.000338	CcSEcCtD
Mitoxantrone—Hypertension—Doxorubicin—urinary bladder cancer	1.65e-05	0.000338	CcSEcCtD
Mitoxantrone—Tachycardia—Epirubicin—urinary bladder cancer	1.64e-05	0.000337	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	1.64e-05	0.000336	CcSEcCtD
Mitoxantrone—Skin disorder—Epirubicin—urinary bladder cancer	1.63e-05	0.000335	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Epirubicin—urinary bladder cancer	1.63e-05	0.000334	CcSEcCtD
Mitoxantrone—Chest pain—Doxorubicin—urinary bladder cancer	1.62e-05	0.000333	CcSEcCtD
Mitoxantrone—Arthralgia—Doxorubicin—urinary bladder cancer	1.62e-05	0.000333	CcSEcCtD
Mitoxantrone—Myalgia—Doxorubicin—urinary bladder cancer	1.62e-05	0.000333	CcSEcCtD
Mitoxantrone—Anxiety—Doxorubicin—urinary bladder cancer	1.62e-05	0.000332	CcSEcCtD
Mitoxantrone—Paraesthesia—Methotrexate—urinary bladder cancer	1.61e-05	0.000331	CcSEcCtD
Mitoxantrone—Discomfort—Doxorubicin—urinary bladder cancer	1.6e-05	0.000329	CcSEcCtD
Mitoxantrone—Anorexia—Epirubicin—urinary bladder cancer	1.6e-05	0.000329	CcSEcCtD
Mitoxantrone—Dyspnoea—Methotrexate—urinary bladder cancer	1.6e-05	0.000329	CcSEcCtD
Mitoxantrone—Somnolence—Methotrexate—urinary bladder cancer	1.6e-05	0.000328	CcSEcCtD
Mitoxantrone—Dyspepsia—Methotrexate—urinary bladder cancer	1.58e-05	0.000325	CcSEcCtD
Mitoxantrone—Hypotension—Epirubicin—urinary bladder cancer	1.57e-05	0.000323	CcSEcCtD
Mitoxantrone—Confusional state—Doxorubicin—urinary bladder cancer	1.57e-05	0.000322	CcSEcCtD
Mitoxantrone—Decreased appetite—Methotrexate—urinary bladder cancer	1.56e-05	0.000321	CcSEcCtD
Mitoxantrone—Oedema—Doxorubicin—urinary bladder cancer	1.56e-05	0.000319	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.56e-05	0.000319	CcSEcCtD
Mitoxantrone—Fatigue—Methotrexate—urinary bladder cancer	1.55e-05	0.000318	CcSEcCtD
Mitoxantrone—Infection—Doxorubicin—urinary bladder cancer	1.55e-05	0.000317	CcSEcCtD
Mitoxantrone—Pain—Methotrexate—urinary bladder cancer	1.54e-05	0.000315	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.53e-05	0.000315	CcSEcCtD
Mitoxantrone—Shock—Doxorubicin—urinary bladder cancer	1.53e-05	0.000314	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.52e-05	0.000313	CcSEcCtD
Mitoxantrone—Tachycardia—Doxorubicin—urinary bladder cancer	1.52e-05	0.000312	CcSEcCtD
Mitoxantrone—Skin disorder—Doxorubicin—urinary bladder cancer	1.51e-05	0.00031	CcSEcCtD
Mitoxantrone—Paraesthesia—Epirubicin—urinary bladder cancer	1.51e-05	0.00031	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	1.5e-05	0.000309	CcSEcCtD
Mitoxantrone—Dyspnoea—Epirubicin—urinary bladder cancer	1.5e-05	0.000308	CcSEcCtD
Mitoxantrone—Somnolence—Epirubicin—urinary bladder cancer	1.49e-05	0.000307	CcSEcCtD
Mitoxantrone—Anorexia—Doxorubicin—urinary bladder cancer	1.48e-05	0.000305	CcSEcCtD
Mitoxantrone—Feeling abnormal—Methotrexate—urinary bladder cancer	1.48e-05	0.000304	CcSEcCtD
Mitoxantrone—Dyspepsia—Epirubicin—urinary bladder cancer	1.48e-05	0.000304	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.47e-05	0.000302	CcSEcCtD
Mitoxantrone—Decreased appetite—Epirubicin—urinary bladder cancer	1.46e-05	0.0003	CcSEcCtD
Mitoxantrone—Hypotension—Doxorubicin—urinary bladder cancer	1.45e-05	0.000298	CcSEcCtD
Mitoxantrone—Fatigue—Epirubicin—urinary bladder cancer	1.45e-05	0.000298	CcSEcCtD
Mitoxantrone—Pain—Epirubicin—urinary bladder cancer	1.44e-05	0.000295	CcSEcCtD
Mitoxantrone—Constipation—Epirubicin—urinary bladder cancer	1.44e-05	0.000295	CcSEcCtD
Mitoxantrone—Urticaria—Methotrexate—urinary bladder cancer	1.43e-05	0.000293	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—urinary bladder cancer	1.42e-05	0.000292	CcSEcCtD
Mitoxantrone—Body temperature increased—Methotrexate—urinary bladder cancer	1.42e-05	0.000292	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.42e-05	0.000291	CcSEcCtD
Mitoxantrone—Paraesthesia—Doxorubicin—urinary bladder cancer	1.4e-05	0.000287	CcSEcCtD
Mitoxantrone—Dyspnoea—Doxorubicin—urinary bladder cancer	1.39e-05	0.000285	CcSEcCtD
Mitoxantrone—Feeling abnormal—Epirubicin—urinary bladder cancer	1.39e-05	0.000285	CcSEcCtD
Mitoxantrone—Somnolence—Doxorubicin—urinary bladder cancer	1.38e-05	0.000284	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.37e-05	0.000282	CcSEcCtD
Mitoxantrone—Dyspepsia—Doxorubicin—urinary bladder cancer	1.37e-05	0.000281	CcSEcCtD
Mitoxantrone—Decreased appetite—Doxorubicin—urinary bladder cancer	1.35e-05	0.000278	CcSEcCtD
Mitoxantrone—Fatigue—Doxorubicin—urinary bladder cancer	1.34e-05	0.000275	CcSEcCtD
Mitoxantrone—Urticaria—Epirubicin—urinary bladder cancer	1.34e-05	0.000274	CcSEcCtD
Mitoxantrone—Pain—Doxorubicin—urinary bladder cancer	1.33e-05	0.000273	CcSEcCtD
Mitoxantrone—Constipation—Doxorubicin—urinary bladder cancer	1.33e-05	0.000273	CcSEcCtD
Mitoxantrone—Abdominal pain—Epirubicin—urinary bladder cancer	1.33e-05	0.000273	CcSEcCtD
Mitoxantrone—Body temperature increased—Epirubicin—urinary bladder cancer	1.33e-05	0.000273	CcSEcCtD
Mitoxantrone—Hypersensitivity—Methotrexate—urinary bladder cancer	1.32e-05	0.000272	CcSEcCtD
Mitoxantrone—Asthenia—Methotrexate—urinary bladder cancer	1.29e-05	0.000265	CcSEcCtD
Mitoxantrone—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.28e-05	0.000263	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.27e-05	0.000261	CcSEcCtD
Mitoxantrone—Hypersensitivity—Epirubicin—urinary bladder cancer	1.24e-05	0.000254	CcSEcCtD
Mitoxantrone—Urticaria—Doxorubicin—urinary bladder cancer	1.24e-05	0.000254	CcSEcCtD
Mitoxantrone—Abdominal pain—Doxorubicin—urinary bladder cancer	1.23e-05	0.000253	CcSEcCtD
Mitoxantrone—Body temperature increased—Doxorubicin—urinary bladder cancer	1.23e-05	0.000253	CcSEcCtD
Mitoxantrone—Diarrhoea—Methotrexate—urinary bladder cancer	1.23e-05	0.000252	CcSEcCtD
Mitoxantrone—Asthenia—Epirubicin—urinary bladder cancer	1.21e-05	0.000248	CcSEcCtD
Mitoxantrone—Diarrhoea—Epirubicin—urinary bladder cancer	1.15e-05	0.000236	CcSEcCtD
Mitoxantrone—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.15e-05	0.000235	CcSEcCtD
Mitoxantrone—Vomiting—Methotrexate—urinary bladder cancer	1.14e-05	0.000235	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—urinary bladder cancer	1.13e-05	0.000233	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—urinary bladder cancer	1.13e-05	0.000232	CcSEcCtD
Mitoxantrone—Headache—Methotrexate—urinary bladder cancer	1.13e-05	0.000231	CcSEcCtD
Mitoxantrone—Asthenia—Doxorubicin—urinary bladder cancer	1.12e-05	0.000229	CcSEcCtD
Mitoxantrone—Vomiting—Epirubicin—urinary bladder cancer	1.07e-05	0.00022	CcSEcCtD
Mitoxantrone—Nausea—Methotrexate—urinary bladder cancer	1.07e-05	0.000219	CcSEcCtD
Mitoxantrone—Diarrhoea—Doxorubicin—urinary bladder cancer	1.06e-05	0.000219	CcSEcCtD
Mitoxantrone—Rash—Epirubicin—urinary bladder cancer	1.06e-05	0.000218	CcSEcCtD
Mitoxantrone—Dermatitis—Epirubicin—urinary bladder cancer	1.06e-05	0.000217	CcSEcCtD
Mitoxantrone—Headache—Epirubicin—urinary bladder cancer	1.05e-05	0.000216	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—ERBB2—urinary bladder cancer	1.04e-05	0.000424	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.03e-05	0.000421	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	1.03e-05	0.000421	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PRSS3—urinary bladder cancer	1.03e-05	0.000421	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	1.02e-05	0.000418	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	1.02e-05	0.000416	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—ATM—urinary bladder cancer	1.01e-05	0.000414	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	1.01e-05	0.000412	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	1e-05	0.000409	CbGpPWpGaD
Mitoxantrone—Nausea—Epirubicin—urinary bladder cancer	9.99e-06	0.000205	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	9.9e-06	0.000405	CbGpPWpGaD
Mitoxantrone—Vomiting—Doxorubicin—urinary bladder cancer	9.89e-06	0.000203	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.83e-06	0.000402	CbGpPWpGaD
Mitoxantrone—Rash—Doxorubicin—urinary bladder cancer	9.81e-06	0.000201	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	9.8e-06	0.000401	CbGpPWpGaD
Mitoxantrone—Dermatitis—Doxorubicin—urinary bladder cancer	9.8e-06	0.000201	CcSEcCtD
Mitoxantrone—Headache—Doxorubicin—urinary bladder cancer	9.74e-06	0.0002	CcSEcCtD
Mitoxantrone—ABCC1—Disease—LIG1—urinary bladder cancer	9.63e-06	0.000394	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	9.61e-06	0.000393	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	9.51e-06	0.000389	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PRSS3—urinary bladder cancer	9.36e-06	0.000383	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	9.36e-06	0.000382	CbGpPWpGaD
Mitoxantrone—Nausea—Doxorubicin—urinary bladder cancer	9.24e-06	0.00019	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—CDKN1A—urinary bladder cancer	9.24e-06	0.000378	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PTEN—urinary bladder cancer	9.22e-06	0.000377	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CDKN1A—urinary bladder cancer	8.87e-06	0.000363	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	8.87e-06	0.000363	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NAT1—urinary bladder cancer	8.87e-06	0.000363	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—PTEN—urinary bladder cancer	8.85e-06	0.000362	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—FGFR3—urinary bladder cancer	8.83e-06	0.000361	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EP300—urinary bladder cancer	8.79e-06	0.000359	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—RB1—urinary bladder cancer	8.76e-06	0.000358	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.71e-06	0.000356	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	8.61e-06	0.000352	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—SRC—urinary bladder cancer	8.55e-06	0.000349	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.53e-06	0.000349	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TYMP—urinary bladder cancer	8.51e-06	0.000348	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.4e-06	0.000344	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.25e-06	0.000337	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TYMP—urinary bladder cancer	8.23e-06	0.000336	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—SRC—urinary bladder cancer	8.21e-06	0.000335	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.17e-06	0.000334	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	8.11e-06	0.000332	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.9e-06	0.000323	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	7.7e-06	0.000315	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.7e-06	0.000315	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—NAT2—urinary bladder cancer	7.69e-06	0.000314	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.67e-06	0.000313	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.63e-06	0.000312	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CREBBP—urinary bladder cancer	7.52e-06	0.000307	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	7.5e-06	0.000306	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EGFR—urinary bladder cancer	7.49e-06	0.000306	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TYMP—urinary bladder cancer	7.48e-06	0.000306	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDH1—urinary bladder cancer	7.46e-06	0.000305	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NAT2—urinary bladder cancer	7.44e-06	0.000304	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ENO2—urinary bladder cancer	7.34e-06	0.0003	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	7.3e-06	0.000299	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	7.28e-06	0.000298	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—EGFR—urinary bladder cancer	7.19e-06	0.000294	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	7.09e-06	0.00029	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—KRAS—urinary bladder cancer	7.08e-06	0.000289	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	7.05e-06	0.000288	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	7.04e-06	0.000288	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.99e-06	0.000286	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—RBX1—urinary bladder cancer	6.96e-06	0.000285	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	6.9e-06	0.000282	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KRAS—urinary bladder cancer	6.8e-06	0.000278	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NAT2—urinary bladder cancer	6.77e-06	0.000277	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	6.72e-06	0.000275	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	6.7e-06	0.000274	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.69e-06	0.000274	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NAT1—urinary bladder cancer	6.68e-06	0.000273	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTO2—urinary bladder cancer	6.68e-06	0.000273	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—RRM2—urinary bladder cancer	6.64e-06	0.000271	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.61e-06	0.00027	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.51e-06	0.000266	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	6.51e-06	0.000266	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—RRM2—urinary bladder cancer	6.42e-06	0.000263	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.42e-06	0.000263	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	6.3e-06	0.000257	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—ERBB2—urinary bladder cancer	6.29e-06	0.000257	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—JAG1—urinary bladder cancer	6.23e-06	0.000255	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ENO2—urinary bladder cancer	6.15e-06	0.000251	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—HPGDS—urinary bladder cancer	6.15e-06	0.000251	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.11e-06	0.00025	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	6.11e-06	0.00025	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—urinary bladder cancer	6.02e-06	0.000246	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—EP300—urinary bladder cancer	5.99e-06	0.000245	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GSTT1—urinary bladder cancer	5.96e-06	0.000244	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ENO2—urinary bladder cancer	5.95e-06	0.000243	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—HPGDS—urinary bladder cancer	5.95e-06	0.000243	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.91e-06	0.000242	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.87e-06	0.00024	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—RRM2—urinary bladder cancer	5.84e-06	0.000239	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	5.84e-06	0.000239	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—urinary bladder cancer	5.78e-06	0.000236	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GSTT1—urinary bladder cancer	5.77e-06	0.000236	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL2—urinary bladder cancer	5.7e-06	0.000233	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.68e-06	0.000232	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.68e-06	0.000232	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.6e-06	0.000229	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.58e-06	0.000228	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.5e-06	0.000225	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.48e-06	0.000224	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—HPGDS—urinary bladder cancer	5.41e-06	0.000221	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ENO2—urinary bladder cancer	5.41e-06	0.000221	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDKN1A—urinary bladder cancer	5.38e-06	0.00022	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TYMP—urinary bladder cancer	5.37e-06	0.00022	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PTEN—urinary bladder cancer	5.37e-06	0.000219	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GSTT1—urinary bladder cancer	5.25e-06	0.000215	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MYC—urinary bladder cancer	5.22e-06	0.000213	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	5.19e-06	0.000212	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EP300—urinary bladder cancer	5.12e-06	0.000209	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PRSS3—urinary bladder cancer	5.06e-06	0.000207	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—SRC—urinary bladder cancer	4.98e-06	0.000203	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—NQO1—urinary bladder cancer	4.96e-06	0.000203	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.95e-06	0.000202	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.91e-06	0.000201	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NAT2—urinary bladder cancer	4.86e-06	0.000199	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.81e-06	0.000197	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NQO1—urinary bladder cancer	4.79e-06	0.000196	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.79e-06	0.000196	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.78e-06	0.000195	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.65e-06	0.00019	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.56e-06	0.000186	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NCOR1—urinary bladder cancer	4.54e-06	0.000185	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.43e-06	0.000181	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EGFR—urinary bladder cancer	4.36e-06	0.000178	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NQO1—urinary bladder cancer	4.36e-06	0.000178	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.34e-06	0.000177	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—urinary bladder cancer	4.29e-06	0.000175	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ERCC2—urinary bladder cancer	4.27e-06	0.000174	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—RRM2—urinary bladder cancer	4.19e-06	0.000171	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.19e-06	0.000171	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GSTP1—urinary bladder cancer	4.13e-06	0.000169	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KRAS—urinary bladder cancer	4.12e-06	0.000168	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.11e-06	0.000168	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.11e-06	0.000168	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.06e-06	0.000166	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TYMP—urinary bladder cancer	4.05e-06	0.000165	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MTHFR—urinary bladder cancer	4.01e-06	0.000164	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4e-06	0.000164	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GSTP1—urinary bladder cancer	4e-06	0.000163	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TERT—urinary bladder cancer	4e-06	0.000163	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.97e-06	0.000162	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	3.88e-06	0.000159	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ENO2—urinary bladder cancer	3.88e-06	0.000159	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.88e-06	0.000159	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.87e-06	0.000158	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TYMS—urinary bladder cancer	3.84e-06	0.000157	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—NCOR1—urinary bladder cancer	3.8e-06	0.000155	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GSTM1—urinary bladder cancer	3.8e-06	0.000155	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	3.77e-06	0.000154	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.76e-06	0.000154	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TYMS—urinary bladder cancer	3.72e-06	0.000152	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.7e-06	0.000151	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NCOR1—urinary bladder cancer	3.67e-06	0.00015	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GSTM1—urinary bladder cancer	3.67e-06	0.00015	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.67e-06	0.00015	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—FGFR3—urinary bladder cancer	3.67e-06	0.00015	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.66e-06	0.00015	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GPX1—urinary bladder cancer	3.64e-06	0.000149	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GSTP1—urinary bladder cancer	3.64e-06	0.000149	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ERCC2—urinary bladder cancer	3.57e-06	0.000146	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GPX1—urinary bladder cancer	3.52e-06	0.000144	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—urinary bladder cancer	3.5e-06	0.000143	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ERCC2—urinary bladder cancer	3.45e-06	0.000141	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.39e-06	0.000139	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TYMS—urinary bladder cancer	3.38e-06	0.000138	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—MTHFR—urinary bladder cancer	3.36e-06	0.000137	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GSTM1—urinary bladder cancer	3.34e-06	0.000137	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NCOR1—urinary bladder cancer	3.34e-06	0.000137	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.26e-06	0.000133	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—MTHFR—urinary bladder cancer	3.25e-06	0.000133	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GPX1—urinary bladder cancer	3.2e-06	0.000131	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.2e-06	0.000131	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.16e-06	0.000129	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ERCC2—urinary bladder cancer	3.14e-06	0.000128	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NQO1—urinary bladder cancer	3.13e-06	0.000128	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CREBBP—urinary bladder cancer	3.12e-06	0.000128	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.12e-06	0.000127	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.95e-06	0.000121	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.93e-06	0.00012	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.93e-06	0.00012	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.84e-06	0.000116	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—RHOA—urinary bladder cancer	2.83e-06	0.000115	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PPARG—urinary bladder cancer	2.72e-06	0.000111	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.66e-06	0.000109	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PPARG—urinary bladder cancer	2.63e-06	0.000108	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CREBBP—urinary bladder cancer	2.62e-06	0.000107	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ERBB2—urinary bladder cancer	2.62e-06	0.000107	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	2.61e-06	0.000107	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTGS2—urinary bladder cancer	2.56e-06	0.000105	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	2.53e-06	0.000103	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.49e-06	0.000102	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TYMS—urinary bladder cancer	2.43e-06	9.93e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	2.4e-06	9.81e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	2.4e-06	9.81e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.4e-06	9.79e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.36e-06	9.64e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.3e-06	9.41e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GPX1—urinary bladder cancer	2.3e-06	9.4e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	2.26e-06	9.22e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.25e-06	9.22e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CDKN1A—urinary bladder cancer	2.24e-06	9.14e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTEN—urinary bladder cancer	2.23e-06	9.12e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTGS2—urinary bladder cancer	2.14e-06	8.76e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EP300—urinary bladder cancer	2.13e-06	8.7e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	2.12e-06	8.67e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	2.07e-06	8.47e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—SRC—urinary bladder cancer	2.07e-06	8.46e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.97e-06	8.04e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.95e-06	7.96e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.88e-06	7.7e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.87e-06	7.64e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MYC—urinary bladder cancer	1.85e-06	7.58e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.83e-06	7.47e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EGFR—urinary bladder cancer	1.81e-06	7.41e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.81e-06	7.39e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.81e-06	7.39e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTEN—urinary bladder cancer	1.81e-06	7.39e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.8e-06	7.37e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.8e-06	7.37e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—EP300—urinary bladder cancer	1.78e-06	7.28e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.75e-06	7.15e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.73e-06	7.08e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—EP300—urinary bladder cancer	1.72e-06	7.04e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.72e-06	7.03e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KRAS—urinary bladder cancer	1.71e-06	7e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.7e-06	6.95e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.65e-06	6.75e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.64e-06	6.72e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.6e-06	6.53e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—EP300—urinary bladder cancer	1.57e-06	6.41e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—urinary bladder cancer	1.46e-06	5.95e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.45e-06	5.94e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.35e-06	5.53e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.3e-06	5.3e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.24e-06	5.09e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.21e-06	4.95e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.18e-06	4.82e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.13e-06	4.61e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.13e-06	4.6e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.11e-06	4.55e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.11e-06	4.55e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.07e-06	4.36e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.05e-06	4.28e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.02e-06	4.17e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.84e-07	4.02e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.89e-07	3.63e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—EP300—urinary bladder cancer	8.47e-07	3.46e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.98e-07	3.26e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.67e-07	3.13e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.28e-07	2.57e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.47e-07	2.24e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.22e-07	2.13e-05	CbGpPWpGaD
